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Abstract
Background: Effects of simvastatin on serum level of adiponectin, a protein conferring benefits in both cardiovascular
and metabolic system, are not fully determined.
Methods: A meta-analysis of randomized controlled trials (RCTs) was performed. Studies were identified by searching
of Pubmed, Embase, and the Cochrane Library databases. Heterogeneity among the RCTs was determined by Cochrane’s
Q test and I2 statistics. Meta-analysis was performed with random-effect model or fixed-effect model according to the
heterogeneity. Meta-regression and subgroup analyses were performed to analyze the source of heterogeneity.
Results: Twelve RCTs with 16 comparisons and 1042 patients were included. Overall, serum adiponectin was not
significantly affected by simvastatin (WMD: 0.42 μg/mL; 95% CI, -0.66–1.50 μg/mL). However, significant heterogeneity
was detected (Cochrane’s Q test: p < 0.01; I2 = 83%). Subsequent meta-regression analyses indicated that treatment
duration was a significant determinant of the effects of simvastatin treatment on serum adiponectin (Coefficient 0.04,
p = 0.03). Subgroup analyses demonstrated that simvastatin treatment was associated with increased adiponectin in
studies with treatment duration of 12 weeks (WMD: 3.65 μg/mL; p < 0.01), but not in studies with treatment duration
of ≤ 8 weeks (WMD: -0.20 μg/mL; p = 0.38). The different between the two stratums was significant (p < 0.01).
Conclusions: Treatment with simvastatin of 12 weeks may increase the serum level adiponectin in patients at risk for
cardiovascular diseases, but not for the short term treatment of ≤ 8 weeks.
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Background
Accumulating evidence from previous clinical trials has
confirmed the role of statins, a class of medications used
to lower low-density-lipoprotein cholesterol (LDL-C)
levels, as the cornerstone for the primary and secondary
prevention of cardiovascular diseases [1, 2]. The subse-
quent studies regarding the mechanisms of statins indi-
cate that many other potential mechanisms contribute
to the benefits of statins in patients at risk for cardiovas-
cular diseases (CVDs), such as anti-inflammation, anti-
oxidation, and stabilization of the atherosclerotic plaques
[3]. Simvastatin, as a representative medication of the
first generation statins, has become one of the most
commonly used statins for the treatment of hypercholes-
terolemia and dyslipidemia [4, 5]. The efficacy and safety
of this medication have been well established in previous
clinical trials [6]. Therefore, further elucidation of its
potential therapeutic mechanisms in patients with car-
diovascular diseases other than lipids-lowering is of sig-
nificance. Recent studies have suggested that simvastatin
may have influence on glucose metabolic pathways, such
as glucose transport, insulin secretion, and insulin resist-
ance [7]. However the potential mechanisms underlying
these effects remain to be determined.
Adiponectin is a protein that is synthesized in adipose
tissue and exerts both the cardiovascular and metabolic
benefits [8, 9]. Previous experimental studies suggest
that the beneficial effects of adiponectin include multiple
mechanisms, such as anti-inflammatory, anti-oxidant, anti-
atherogenic, and anti-thrombotic, as well as improving
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insulin resistance and anti-diabetes [10]. Consistently,
higher plasma level of adiponectin has been related to
the decreased risks of CVDs and diabetes mellitus
(DM) [11, 12], suggesting the potential role of adipo-
nectin as an important target for the prevention and
treatment of CVDs and DM. Previous studies have sug-
gested that simvastatin treatment may affect serum
level of adiponectin [13–24]. However, these studies are
generally of limited scale and results of these studies
are not always consistent. Therefore, in this study, we
performed a meta-analysis to evaluate the effect of sim-
vastatin on serum level adiponectin. The results of our
study may be of significance to further elucidate the po-
tential mechanisms of potential influence of simvastatin
on cardiovascular and metabolic systems.
Methods
Database searching
This systematic review and meta-analysis was performed
in accordance with the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) state-
ment [25] and the Cochrane’s Handbook of Systematic
Review and Meta-analyses [26]. We searched the
Pubmed, Embase, and Cochrane Library databases with
the words “simvastatin” paired with “adiponectin”, which
were limited to studies in humans. The final search was
completed on Nov 20th, 2016. The references of the
original studies were manually screened for possible
relevant studies.
Inclusion and exclusion criteria
In accordance with the aim of the meta-analysis, studies
were included if they met all of the following criteria: (a)
designed as RCTs and published as full-length article in
English; (b) included participants randomized to simva-
statin (with no limitations to the dose and treatment
duration) or control group; (c) circulating adiponectin
levels were reported; and (d) data (means and standard
deviations [SDs]) regarding changes of adiponectin from
baseline were reported or could be calculated. Reviews,
nonhuman studies, observational studies without longi-
tudinal follow-up, cross-sectional studies, duplicate pub-
lications, and studies in which changes of adiponectin
were not reported or unavailable were excluded.
Data extraction and quality evaluation
The database searching, data extraction and study quality
evaluation were independently performed by two authors
(WC and ZH), and the discrepancies were resolved by
consensus. For studies with more than one intervention
group (e.g. different statin dosages), multiple comparisons
were considered and the controls were split into mul-
tiple groups to overcome a unit of analysis error [26].
Data regarding study design, patient characteristics
(health status, number of participants, mean age, gender,
mean body mass index [BMI]), intervention strategies
(dosages, and treatment durations), adiponectin measure-
ment methods and the type of adiponectin measured were
extracted. The seven domains of the Cochrane Risk of
Bias Tool was applied to evaluate the quality of the in-
cluded RCTs, which addressing aspects of sequence gener-
ation, allocation concealment, participant and personnel
blinding, outcome assessor blinding, incomplete outcome
data, selective outcome reporting, and other potential
threats to validity.
Statistics
The main outcome for the current meta-analysis was the
change of serum adiponectin level between baseline and
endpoint in response to statin therapy as compared with
controlled. The pooled effect was expressed as weighted
mean difference (WMD) with 95% confidence intervals
(CI). Heterogeneity among the included studies was
formally tested using Cochrane’s Q test, and significant
heterogeneity was considered if p values < 0.10 [26]. The
I2 statistic, which describes the percentage of total vari-
ation across studies that is due to heterogeneity rather
than chance, was also examined, and values of I2 > 50%
indicated significant heterogeneity [27]. A random-effect
was applied to estimate the overall outcome if I2 > 50%,
otherwise, a fixed-effect model was used. To identify
whether differences in study characteristics were poten-
tial contributors to heterogeneity, we performed univari-
ate meta-regression and subgroup analyses subsequently,
and predefined study characteristics included age, gender,
mean BMI, and dosage and treatment duration of simva-
statin. Potential publication bias was assessed with a
funnel plot and Egger’s regression asymmetry test [28].
P values were two-tailed and statistical significance was
set at 0.05. The meta-analysis and statistical analysis were
performed with RevMan software (Version 5.3; Cochrane
Collaboration, Oxford, UK) and Stata software (version
12.0; Stata Corporation, College Station, TX, USA).
Results
Database searching
The process of database searching and study identification
was shown in Fig. 1. Briefly, 174 records were retrieved
after initial database searching and 12 RCTs [13–24] were
finally included. Two of the included studies [18, 21] had
more than one interventional arm with different doses of
simvastatin, and multiple comparisons were included.
Study characteristics and quality evaluation
The characteristics of the included studies were summa-
rized in Table 1. Briefly, these RCTs generally included pa-
tients at risk for CVDs, such as those with hypertension,
hypercholesterolemia, diabetes, or carotid atherosclerosis.
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The mean ages of the patients varied from 45 to 60 years,
and the BMI ranged from 24 to 39 Kg/m2. Simvastatin
was administered in the treatment group with the doses of
10, 20, 40 and 80 mg/d, and durations of 2 to 12 weeks.
The serum adiponectin was measured via enzyme-linked
immunosorbent assay in most of the included studies, and
the total circulating adiponectin levels were measured in
all of the included studies. The quality of the study as eval-
uated by the Cochrane risk of biases tool was presented in
Table 2, and the overall quality of the included studies
were moderate.
Effects of simvastatin treatment on serum adiponectin
Overall, 16 comparisons with 594 patients in the simva-
statin group and 448 in the control group were included
in the meta-analysis. Significant heterogeneity was de-
tected (Cochrane’s Q test: p < 0.01; I2 = 83%); therefore,
the random-effect model was applied. The pooled results
indicated that serum adiponectin was not significantly
affected by simvastatin (WMD: 0.42 μg/mL; 95% CI,
-0.66–1.50 μg/mL; p = 0.45; Fig. 2). Pooled results with
only double-blinded, placebo-controlled trials [13–16,
18, 23] retrieved similar results (WMD: -0.15 μg/mL;
95% CI, -0.64–0.34 μg/mL; p = 0.54).
Treatment duration and the effects of simvastatin
treatment on serum adiponectin
In view of significant heterogeneity among the included,
we subsequently performed univariate meta-regression
analyses to explore the potential source of heterogeneity.
We found that simvastatin treatment duration was a sig-
nificant determinant of the effects of simvastatin treat-
ment on serum adiponectin (Coefficient 0.04, p = 0.03;
Table 3), but were not for other potential variables such
as age, gender, BMI, or dosages of simvastatin. Specific-
ally, longer treatment duration was associated with more
remarkable increment of adiponectin following simva-
statin, which may partly explain the heterogeneity.
This was confirmed by results of subgroup analyses
which demonstrated that simvastatin treatment was
associated with increased adiponectin in studies with
treatment duration of 12 weeks (WMD: 3.65 μg/mL;
95% CI, 2.14–5.16 μg/mL; p < 0.01; I2 = 48%; Fig. 2),
but not in studies with treatment duration of ≤ 8 weeks
(WMD: -0.20 μg/mL; 95% CI, -0.65–0.25 μg/mL; p = 0.38;
I2 = 0%; Fig. 2). The different between the two stratums
was significant (p < 0.01).
Publication bias
No significant publication biases were indicated by the
funnel plots (Fig. 3) or the results of Egger’s significance
tests for the effects of individual simvastatin treatment
on circulating adiponectin (p = 0.47).
Discussion
In this study, by pooling the results of previous pub-
lished studies, the overall results of the meta-analysis
showed that simvastatin treatment was not associated
with significant change of adiponectin in patients at risk
for CVDs. However, considerable heterogeneity exists
among these studies, and results of subsequent analyses
suggested that treatment duration may influence the
effect of simvastatin treatment on serum adiponectin.
Indeed, subgroup analyses indicated that simvastatin
treatment was associated with significantly enhanced
adiponectin level in studies with treatment duration of
12 weeks, but not in those of ≤ 8 weeks. These results
suggested that simvastatin may enhance the serum level
of adiponectin at least after 12 weeks of treatment dur-
ation, and chronic benefits of simvastatin in cardiovascu-
lar and metabolic systems may involve the regulation of
serum adiponectin.
Our study has clinical relevance in the following as-
pects. Firstly, a previous meta-analysis indicated that
patients with higher serum level of adiponectin were
with a 17% lower risk of coronary artery disease (CAD)
[12]. Therefore, the preventative effects of simvastatin
on CAD may be related to their stimulatory effect on
adiponectin. Interestingly, recent studies have indicated
an inverse association between serum adiponectin levels
and carotid intima-media thickness, an early manifest-
ation of atherosclerosis [29]. Secondly, long-term adminis-
tration of simvastatin has been reported to be associated
Fig. 1 Process of literature searching
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with increased new-onset diabetes (NOD), although the
mechanisms were not clear [30]. In view of the important
role of adiponectin in pathogenesis of insulin resistance
and DM, suppression of serum adiponectin has been pro-
posed to be potential mechanisms underlying the effects
of statins on NOD [31]. Our studies did not support that
simvastatin was associated with decreased serum adipo-
nectin, which indicated that simvastatin may increase the
risk NOD via mechanisms other than suppression of adi-
ponectin. Finally, the enhanced serum level of adiponectin
was observed in studies with simvastatin treatment of 12
weeks, suggesting that future studies regarding the poten-
tial benefits of simvastatin in CVDs should at least be
performed with 12-week of medication administration.
The potential mechanisms underlying regulatory effect
of chronic simvastatin treatment on adiponectin were
not fully understood at this stage, although the findings
of some experimental studies may provide some evi-
dence. An early in vitro study found that simvastatin
could significantly increase the lipopolysaccharide-
induced adiponectin secretion and mRNA expression in
a dose-dependent manner, indicating that simvastatin
could exert beneficial effects on prevention of obesity-
induced metabolic changes in adipocytes [32]. Another
in vitro study indicated that simvastatin counteracted
the stimulatory effect of tumor necrotic factor α on se-
cretion and expression of adiponectin, implying a poten-
tial anti-atherogenic effect during the inflammatory
process [33]. Of note, these in vitro studies were per-
formed to investigation the acute effect of simvastatin
on adipocytes. Future in vivo studies with chronic ad-
ministration of simvastatin are warranted to clarify the
mechanisms underlying the regulatory effect of simva-
statin on adiponectin.
Our study has limitations which should be noted when
interpreting the results. Firstly, the quality of the in-
cluded RCTs was modest and the scales of the studies
Fig. 2 Forest plot for the estimation of the effect of simvastatin treatment of serum adiponectin stratified by the treatment duration
Table 3 Impact of study characteristics to the effects of statins
therapy on serum adiponectin concentrations: results of univariate
meta-regression analyses
WMD of serum adiponectin
concentrations (ug/ml)
Study characteristics Coefficient 95% CI p
Mean age (years) −0.07 −0.22 to 0.09 0.36
Male (%) 0.03 −0.04 to 0.10 0.36
BMI (kg/m2) 0.03 −0.23 to 0.29 0.79
Dose (mg/d) 0.04 −0.03 to 0.11 0.24
Duration (weeks) 0.40 0.05 to 0.74 0.03
Abbreviations: WMD weighed mean difference, CI confidence interval,
BMI body mass index
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were small. Further RCTs with high quality and adequate
sample size are needed to confirm our results. Secondly,
the follow-up durations of the RCTs were up to 12
weeks. Effects of simvastatin on serum adiponectin be-
yond 12 weeks deserve further investigation. Thirdly,
many other factors, such as concurrent medications, diet
factors, exercise habits, and sex hormone levels may
modify the effects of simvastatin on serum adiponectin
levels, but this was difficult to control and may have
contributed to confounding of the results. Finally, effects
of other statins on circulating adiponectin deserve fur-
ther evaluation.
Conclusions
In conclusion, treatment with simvastatin of 12 weeks
may increase the serum level adiponectin in patients at
risk for cardiovascular diseases, but not for the short
term treatment of ≤ 8 weeks. These results suggest that
chronic benefits of simvastatin in cardiovascular and
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